Strategically Designed Panel for the Optimal Management of Thyroid Nodules. And now, newly added TERT and ALK mutations can reliably help to predict aggressive biological features of thyroid cancer.
Interpace Diagnostics is the only company that offers:
Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) — Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue
In-Network Access for More Than 3 Million Members Parsippany, NJ, March 10, 2020 (GLOBE NEWSWIRE) — Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has
Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s ThyGeNEXT® and ThyraMIR® tests in the
Interpace Diagnostics is a registered trademark and business unit of Interpace Biosciences, Inc.™
©2019 Interpace Biosciences, Inc.™ All rights reserved.
